Physician profile
Srikanth Bathula
NPI 1710290036
$3,282.79
in general payments reported to CMS, 2019-2025
11 companies · $355 in 2025
The $355 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,016 · 2021: $99.90 · 2022: $467 · 2023: $911 · 2024: $434 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,700.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $766.21 | 2019 | |
| Abbvie INC. | $574.83 | 2021-2024 | Rinvoq, Skyrizi |
| Glaxosmithkline, LLC. | $459.05 | 2022-2025 | Benlysta, Nucala |
| Amgen INC. | $424.83 | 2023-2025 | Tavneos |
| Astrazeneca Pharmaceuticals Lp | $249.89 | 2022-2023 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.43 | 2023-2024 | |
| Celgene Corporation | $127.97 | 2019 | |
| Janssen Biotech, INC. | $125.00 | 2023 | Simponi Aria |
| Ucb, INC. | $124.97 | 2025 | Bimzelx |
| Radius Health, INC. | $121.83 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $91.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srikanth Bathula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.